AMANDA MISIAK: Open Payments
NPI 1679856983 · READING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,202 in 124 payments from 18 companies in 2025. Trend: 2023 $2,781 · 2024 $2,307 · 2025 $2,202
Food & beverage: $2,202
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 53 | $895 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 24 | $399 |
| Gilead Sciences, Inc. | 9 | $161 |
| Janssen Biotech, Inc. | 8 | $144 |
| Ardelyx, Inc. | 6 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $107 |
| Ipsen Biopharmaceuticals, Inc | 3 | $64 |
| Lilly USA, LLC | 3 | $54 |
| QOL Medical, LLC | 2 | $40 |
| Celltrion USA Inc. | 2 | $38 |
Products named: XIFAXAN, RINVOQ, LINZESS, MAVYRET, TREMFYA, IBSRELA, CREON, IQIRVO.
Industry payments across PA — which companies pay providers there.
